![](https://monteverdelaw.com/wp-content/uploads/atreca-logo.jpg)
Atreca, Inc. (Nasdaq: BCEL), relating to its proposed sale to Immunome, Inc. Under the terms of the agreement, BCEL is expected to be paid up to $12.5 million dollars.
Atreca, Inc. (Nasdaq: BCEL), relating to its proposed sale to Immunome, Inc. Under the terms of the agreement, BCEL is expected to be paid up to $12.5 million dollars.